Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)
On ABGC's listListed on the ABGC Self-Study GuideLog in to starLast updated Nov 4, 2026
A newborn presents with cardiomyopathy and hypoglycemia. Acylcarnitine profile shows elevated C14:1.
AR; ACADVL (very long-chain acyl-CoA dehydrogenase). Biallelic loss-of-function variants; the residual enzyme activity they leave sets the phenotype.
Very long-chain acyl-CoA dehydrogenase (VLCAD) is a homodimer on the inner mitochondrial membrane that performs the first of the four steps of beta-oxidation for fatty acids 14 to 20 carbons long, passing electrons through ETF to the respiratory chain. Sitting at the entry of the spiral, it controls both the electron supply to the respiratory chain and the acetyl-CoA the liver turns into ketones.
Loss of this step shows up in the tissues that must switch to fat when fasting, illness, cold, or exercise raise demand:
- Heart: cannot maintain output, giving hypertrophic or dilated cardiomyopathy and arrhythmia in the severe early-onset form.
- Liver: cannot make ketones, giving hypoketotic hypoglycemia.
- Skeletal muscle: cannot meet exercise demand, giving episodic rhabdomyolysis, probably the most common form overall.
Severity follows residual activity. Severe disease comes with no residual activity, often from null variants (about 81% of truncating variants are found in the severe early-onset form). Milder childhood and adult forms keep some activity; the most common variant, the missense p.Val283Ala, usually gives a non-cardiac phenotype. Homozygous p.Cys237Arg is a missense exception linked to cardiac disease.
Part of fatty acid beta-oxidation.
Mitochondrial fatty acid beta-oxidation, the first step of the long-chain spiral.
long-chain fatty acyl-CoA (14 to 20 carbons, carried in by the carnitine shuttle) → very long-chain acyl-CoA dehydrogenase (the block; FAD cofactor) → enoyl-CoA → trifunctional protein (hydratase, LCHAD, thiolase) → acetyl-CoA plus an acyl-CoA two carbons shorter → ketone bodies and Krebs cycle
- Accumulates: long-chain acyl-CoAs, measured as acylcarnitines: C14:1 is the main newborn screening marker, with C14:2, C14, and C12:1.
- Missing: acetyl-CoA for ketones and electrons for the respiratory chain, so fasting brings hypoketotic hypoglycemia and energy failure in heart and muscle.
- Workbook: 5.H. VLCAD deficiency
- Three phenotypes:
- Severe: Cardiomyopathy, hepatopathy, hypoglycemia (neonatal)
- Moderate: Hypoketotic hypoglycemia (childhood)
- Mild: Myopathy, rhabdomyolysis (adult)
- On RUSP
- Newborn screening (acylcarnitine profile): elevated C14:1 (tetradecenoylcarnitine)
- During crisis: hypoketotic hypoglycemia; CK elevation with rhabdomyolysis in the myopathic form
- Confirmatory: ACADVL molecular testing and/or enzyme activity assay in fibroblasts/leukocytes
- Avoid fasting, MCT supplementation, carnitine (controversial)
NBS: C14:1 (tetradecenoylcarnitine): on newborn screening acylcarnitine profile, elevated C14:1 is the key marker for VLCADD. Compare with MCADD (C8) and LCHADD (C16-OH).
"Very Large Colon ADDs diagnostic value": the colon (":") in C14**:1** is VLCAD's special add-on. LCHAD and VLCAD both have "special" add-ons to their fatty acid biomarkers: LCHAD has "-OH" (C14-OH, C16-OH, C18-OH) and VLCAD has ":" (C14:1).
No retinopathy in VLCADD: unlike LCHADD, VLCADD does not cause retinopathy or peripheral neuropathy. Think "eye chart" for LCHAD (has retinopathy) versus VLCAD (does not).
The "LCD" in VLCADD encodes the 3 major phenotypes: Lysis of muscle (rhabdomyolysis), CArdiomyopathy, and Dip in glucose (hypoglycemia).
